Ezetimibe magani ne wanda yakan rage matakan cholesterol . An amincewa da FDA tun 2002, kuma ana sayar da ita azaman magani ne kawai (Zeta) a hade tare da simvastatin ( maganin magunguna) kamar Vytorin. Duk da haka, azetimibe ya kasance mai rikicewa tun lokacin gabatarwarsa, kuma masana har yanzu suna jayayya game da wurin da yake dacewa wajen magance cututtukan lipid.
Gaskiya
Ayetimibe yayi aiki ta hanyar hana tsinkayen cholesterol daga intestines.
Yawancin lokaci, ƙwayar cholesterol wanda aka ɗauka daga hanji yana ɗauke da ƙwayoyin chylomicrons zuwa hanta, inda aka yi amfani dashi don matakai masu yawa. Lokacin da adadin cholesterol din ya rage ta azetimibe, hanta zai sami wadataccen cholesterol ta cire shi daga lipoproteins da ke cikin jini. Saboda haka, an rage yawan jini na cholesterol.
Kullum, ezetimibe ta hanyar kanta ko a hade tare da statin rage adadin LDL cholesterol a cikin jini ta kimanin 15%.
Hanyoyin Kyau na Ezetimibe
Gaba ɗaya, azetimibe yana da haƙuri. Jiɗa, zawo, da kuma rashin lafiyan halayen iya faruwa. Yayin da aka ruwaito myopathy (cututtukan ƙwayoyin tsoka) tare da ezetimibe, kamar misalin da ake gani da maganin myopathy da statins , matsalar da wannan matsalar ta kasance ya fi kasa da statins. A gaskiya ma, azetimibe za a iya karawa zuwa statin low-dose don cimma burin zazzaɓin cholesterol wanda ba a taɓa ganin myopathy a wasu lokuta ba tare da tsinkayen kwayoyin jini.
Kwayar da Ezetimibe
Lokacin da aka amince da izetimibe, an sayar da shi kamar Vytorin (ezetimibe da simvastatin), kuma tallace-tallace sun kasance brisk. Kuna iya tunawa da tallace-tallace akai-akai a lokacin kwatanta ƙarancin mai juyayi, Aunt Suzie zuwa wani babban ɓangaren bishiyoyi na strawberry a yanayin. Wannan shi ne Vytorin.
Ya bayyana cewa, yayin da waɗannan tallace-tallace suke gudana yayin da Merck ke sayar da biliyoyin daloli na Vytorin, ana jinkirta bugawa (wanda ba shakka ba ne, wani ya ce) wani jarrabawar jarrabawar Merck-sponsored da ake kira binciken ENHANCE. HANYAR da nufin tabbatar da cewa Vytorin inganta siffofin atherosclerotic fiye da simvastatin kadai. Lokacin da aka saki sakamakon a shekarar 2008, an koyi cewa mutanen da ke tare da Vytorin sunyi muni (ba mafi kyau) ba fiye da wadanda ke karbar simvastatin kadai.
Saboda wadannan sakamako masu banza (da kuma cewa mutane da dama suna la'akari da jinkirin bayar da rahoton waɗannan sakamakon shine a kalla ba tare da dalili ba), tallace-tallace na azetimibe aka tanada. Kuma tallace-tallace sun ɓace gaba daya.
Samun sha'awa a cikin ezetimibe ya farfado har zuwa shekara ta 2014, lokacin da aka buga sakon sakamakon jarrabawar IMPROVE-IT. A cikin wannan gwaji, marasa lafiya da ciwon ciwon hauka (ACS) sun kasance bazuwar don samun ko dai Vytorin ko simvastatin kadai. Bayan shekaru 6, marasa lafiya da suka karbi Vytorin sun inganta ingantaccen yanayin asibitoci (ƙananan karatu ga ACS, da kuma rashin bukatar yin gyare-gyare ta hanyar tiyata ko ma'ana ), amma babu wani bambanci a rayuwa.
Wani rukuni na rukuni na jarrabawar da aka dauka -Ya nuna cewa kusan marasa lafiya da aka gani a cikin ƙungiyar Vytorin zasu iya lissafta su da masu ciwon sukari.
A cikin mutane ba tare da ciwon sukari ba, ba za a iya amfana da ƙara azetimibe ba.
Yaushe Ya kamata a Yi Amfani?
Gaba ɗaya, yin amfani da ezetimibe ya kamata a taƙaita shi. Sharuɗɗan da aka buga a shekarar 2013 akan cholesterol ba su bayar da shawarar maganin kowane matakin ƙwayar cholesterol ba. Maimakon haka, suna mayar da hankalin yin la'akari da yin amfani da magungunan statin ko a'a. Saboda haka "ƙwayoyin cholesterol-lowering-drops kamar ezetimibe suna da wuri kadan a karkashin wadannan jagororin. Doctors a wasu lokuta sukan rubuta azetimibe da ƙananan statins a cikin mutanen da ya kamata su kasance a cikin kashi-kashi na kashi, amma ba za su iya jurewa ba.
Har ila yau, ana amfani da azetimibe a maimakon lokuta maimakon statins a cikin marasa lafiya wadanda ba za su iya daukar kwayin a kowane kashi ba.
A ƙarshe, a kan nazarin shirin IMPROVE-IT, mutane da dama suna ganin cewa yana da kyau a yi amfani da azetimibe tare da statin a cikin marasa lafiya na ciwon sukari waɗanda suka samu ACS kwanan nan.
Baya ga waɗannan ƙananan yanayin asibitoci, yanzu babu dalilin da ya dace don ɗaukar hoto.
> Sources:
> Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Ƙara zuwa Cutar Farko bayan Bayanin Harshen Coronary Syndromes. N Engl J Med 2015; 372: 2387.
> Kastelein JJ, Akdim F, Stroes ES et al .; GASKIYA masu bincike: Simvastatin tare da ba tare da Ezetimibe ba a Hypercholesterolemia na iyali. N. Engl. J. Med. 358, 1431-1443 (2008).